blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3645018

EP3645018 - NANODIAMONDS AS ARTIFICIAL PROTEINS FOR REGULATION OF A CELL SIGNALLING SYSTEM [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.05.2024
Database last updated on 03.06.2024
FormerThe patent has been granted
Status updated on  16.06.2023
FormerGrant of patent is intended
Status updated on  23.02.2023
FormerExamination is in progress
Status updated on  24.12.2021
FormerRequest for examination was made
Status updated on  03.04.2020
FormerThe international publication has been made
Status updated on  05.10.2019
Formerunknown
Status updated on  03.04.2019
Most recent event   Tooltip24.05.2024Lapse of the patent in a contracting state
New state(s): IT		published on 26.06.2024 [2024/26]
24.05.2024No opposition filed within time limitpublished on 26.06.2024 [2024/26]
Applicant(s)For all designated states
Ustav organicke chemie a biochemie AV CR, v.v.i.
Flemingovo nam. 2
166 10 Praha 6 / CZ
For all designated states
Masarykova Univerzita
Zerotinovo namesti 2
60177 Brno / CZ
For all designated states
FAKULTNI NEMOCNICE U SV. ANNY V BRNE
Pekarska 53
656 91 Brno / CZ
[2020/19]
Inventor(s)01 / CIGLER, Petr
Komornicka 5
16000 Praha 6 / CZ
02 / BALEK, Lukas
Nerudova 741
74283 Klimkovice / CZ
03 / HAVLIK, Jan
Konice 136
66902 Znojmo / CZ
04 / KREJCI, Pavel
Podoli 391
66403 Brno / CZ
05 / TRANTIREK, Lukas
Masarykova univerzita
Kamenice 753/5
62500 Brno / CZ
06 / TRANTIRKOVA, Silvie
Masarykova univerzita
Kamenice 753/5
62500 Brno / CZ
 [2023/29]
Former [2020/19]01 / CIGLER, Petr
Komornicka 5
16000 Praha 6 / CZ
02 / BALEK, Lukas
Nerudova 741
74283 Klimkovice / CZ
03 / HAVLIK, Jan
Konice 136
66902 Znojmo / CZ
04 / KREJCI, Pavel
Podoli 391
66403 Brno / CZ
05 / TRANTIREK, Lukas
Masarykova univerzita Kamenice 753/5
62500 Brno / CZ
06 / TRANTIRKOVA, Silvie
Masarykova univerzita Kamenice 753/5
62500 Brno / CZ
Representative(s)Hartvichova, Katerina
HARBER IP s.r.o.
Dukelskych hrdinu 567/52
170 00 Praha 7 / CZ
[2020/19]
Application number, filing date19712598.226.03.2019
[2020/19]
WO2019EP57649
Priority number, dateEP2018016529930.03.2018         Original published format: EP 18165299
[2020/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019185667
Date:03.10.2019
Language:EN
[2019/40]
Type: A1 Application with search report 
No.:EP3645018
Date:06.05.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 03.10.2019 takes the place of the publication of the European patent application.
[2020/19]
Type: B1 Patent specification 
No.:EP3645018
Date:19.07.2023
Language:EN
[2023/29]
Search report(s)International search report - published on:EP03.10.2019
ClassificationIPC:A61K33/44, A61K9/14, A61K45/06, A61P35/00
[2023/10]
CPC:
A61K33/44 (EP,US); A61K45/06 (EP,US); A61K9/14 (EP,US);
A61P35/00 (EP); C07K14/50 (US)
Former IPC [2020/19]A61K33/44, A61P35/00, A61K9/14
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/19]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:NANODIAMANTEN ALS KÜNSTLICHE PROTEINE ZUR REGULATION EINES ZELLSIGNALISIERUNGSSYSTEMS[2020/19]
English:NANODIAMONDS AS ARTIFICIAL PROTEINS FOR REGULATION OF A CELL SIGNALLING SYSTEM[2020/19]
French:NANODIAMANTS COMME PROTÉINES ARTIFICIELLES POUR LA RÉGULATION D'UN SYSTÈME DE SIGNALISATION DE CELLULES[2023/10]
Former [2020/19]NANODIAMANTS EN TANT QUE PROTÉINES ARTIFICIELLES POUR LA RÉGULATION D'UN SYSTÈME DE SIGNALISATION CELLULAIRE
Entry into regional phase27.01.2020National basic fee paid 
27.01.2020Designation fee(s) paid 
27.01.2020Examination fee paid 
Examination procedure27.01.2020Amendment by applicant (claims and/or description)
27.01.2020Examination requested  [2020/19]
27.01.2020Date on which the examining division has become responsible
03.01.2022Despatch of a communication from the examining division (Time limit: M04)
19.04.2022Reply to a communication from the examining division
30.08.2022Despatch of a communication from the examining division (Time limit: M04)
24.10.2022Reply to a communication from the examining division
24.02.2023Communication of intention to grant the patent
05.06.2023Receipt of the translation of the claim(s)
09.06.2023Fee for grant paid
09.06.2023Fee for publishing/printing paid
Opposition(s)22.04.2024No opposition filed within time limit [2024/26]
Fees paidRenewal fee
15.02.2021Renewal fee patent year 03
30.03.2022Renewal fee patent year 04
24.03.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT19.07.2023
DK19.07.2023
EE19.07.2023
ES19.07.2023
FI19.07.2023
HR19.07.2023
IT19.07.2023
LT19.07.2023
LV19.07.2023
NL19.07.2023
PL19.07.2023
RO19.07.2023
RS19.07.2023
SE19.07.2023
SK19.07.2023
SM19.07.2023
NO19.10.2023
GR20.10.2023
IS19.11.2023
PT20.11.2023
[2024/26]
Former [2024/23]AT19.07.2023
DK19.07.2023
EE19.07.2023
ES19.07.2023
FI19.07.2023
HR19.07.2023
LT19.07.2023
LV19.07.2023
NL19.07.2023
PL19.07.2023
RO19.07.2023
RS19.07.2023
SE19.07.2023
SK19.07.2023
SM19.07.2023
NO19.10.2023
GR20.10.2023
IS19.11.2023
PT20.11.2023
Former [2024/22]AT19.07.2023
DK19.07.2023
FI19.07.2023
HR19.07.2023
LT19.07.2023
LV19.07.2023
NL19.07.2023
PL19.07.2023
RO19.07.2023
RS19.07.2023
SE19.07.2023
SM19.07.2023
NO19.10.2023
GR20.10.2023
IS19.11.2023
PT20.11.2023
Former [2024/20]AT19.07.2023
FI19.07.2023
HR19.07.2023
LT19.07.2023
LV19.07.2023
NL19.07.2023
PL19.07.2023
RS19.07.2023
SE19.07.2023
SM19.07.2023
NO19.10.2023
GR20.10.2023
IS19.11.2023
PT20.11.2023
Former [2024/10]AT19.07.2023
FI19.07.2023
HR19.07.2023
LT19.07.2023
LV19.07.2023
NL19.07.2023
PL19.07.2023
RS19.07.2023
SE19.07.2023
NO19.10.2023
GR20.10.2023
IS19.11.2023
PT20.11.2023
Former [2024/09]AT19.07.2023
FI19.07.2023
LT19.07.2023
NL19.07.2023
SE19.07.2023
NO19.10.2023
GR20.10.2023
IS19.11.2023
Former [2024/08]LT19.07.2023
NL19.07.2023
NO19.10.2023
GR20.10.2023
Former [2024/05]NL19.07.2023
Cited inInternational search[A]WO2014191633  (CARBODEON LTD OY [FI]) [A] 1-20 * claim - *;
 [X]US2015182624  (PETIT TRISTAN [FR], et al) [X] 1,3-13,15-20 * paragraphs [0009] , [0 41] , [0 73]; figures 4,5; claim - *;
 [AD]  - L. MOORE ET AL, "Multi-protein Delivery by Nanodiamonds Promotes Bone Formation", JOURNAL OF DENTAL RESEARCH, US, (20130917), vol. 92, no. 11, doi:10.1177/0022034513504952, ISSN 0022-0345, pages 976 - 981, XP055478721 [AD] 1-20 * page 977; figure 1 *

DOI:   http://dx.doi.org/10.1177/0022034513504952
 [A]  - Mateusz Wierzbicki ET AL, "Comparison of anti-angiogenic properties of pristine carbon nanoparticles", Nanoscale Research Letters, New York, doi:10.1186/1556-276X-8-195, (20131201), pages 1 - 8, URL: https://nanoscalereslett.springeropen.com/track/pdf/10.1186/1556-276X-8-195, XP055478747 [A] 1-20 * abstract * * table 1 *

DOI:   http://dx.doi.org/10.1186/1556-276X-8-195
 [A]  - ANDRÉ CHWALIBOG ET AL, "Carbon nanoparticles downregulate expression of basic fibroblast growth factor in the heart during embryogenesis", INTERNATIONAL JOURNAL OF NANOMEDICINE, (20130901), doi:10.2147/IJN.S49745, page 3427, XP055478735 [A] 1-20 * abstract * * page 3428, column r *

DOI:   http://dx.doi.org/10.2147/IJN.S49745
by applicant   - ORNITZ, D. M.; MARIE, P. J., Genes Dev., (20150000), vol. 29, page 1463
    - WESCHE, J. et al., Biochem. J., (20110000), vol. 437, page 199
    - Cancer Lett., (20110801), vol. 307, no. 1, pages 47 - 52
    - Int J Cancer., (20100215), vol. 126, no. 4, pages 1004 - 16
    - Oncotarget, (20170228), vol. 8, no. 9, pages 16052 - 16074
    - DOBROVOLSKAIA, M. A. et al., Molecular Pharmaceutics, (20080000), vol. 5, page 487
    - L. MOORE et al., J. Dent. Res., (20130000), vol. 92, page 976
    - KREJCI, P. et al., "Mammalian Cell-Based Assay for Identification of Inhibitors of the Erk MAP Kinase Pathway", Invest. New Drugs, (20070000), vol. 25, pages 391 - 39
    - GUAGNANO, V.; FURET, P.; SPANKA, C.; BORDAS, V.; LE DOUGET, M.; STAMM, C.; BRUEGGEN, J.; JENSEN, M. R.; SCHNELL, C.; SCHMID, H. et, "Discovery of 3-(2,6-Dichloro-3,5-Dimethoxy-Phenyl)-1-16-[4-(4-Ethyl-Piperazin-1-Yl)-Phenylamino]-Pyrimidin-4-Yl}-l-Methyl-Urea (NVP-BGJ398), a Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase", J. Med. Chem., (20110000), vol. 54, doi:doi:10.1021/jm2006222, pages 7066 - 7083, XP002689272

DOI:   http://dx.doi.org/10.1021/jm2006222
    - TANNER, Y.; GROSE, R. P., "Dysregulated FGF Signalling in Neoplastic Disorders", Semin. Cell Dev. Biol., (20160000), vol. 53, doi:doi:10.1016/j.semcdb.2015.10.012, pages 126 - 135, XP029540048

DOI:   http://dx.doi.org/10.1016/j.semcdb.2015.10.012
    - KREJCI, P.; PROCHAZKOVA, J.; SMUTNY, J.; CHLEBOVA, K.; LIN, P.; AKLIAN, A.; BRYJA, V.; KOZUBIK, A.; WILCOX, W. R., "FGFR3 Signaling Induces a Reversible Senescence Phenotype in Chondrocytes Similar to Oncogene-Induced Premature Senescence", Bone, (20100000), vol. 47, doi:doi:10.1016/j.bone.2010.03.021, pages 102 - 110, XP027074961

DOI:   http://dx.doi.org/10.1016/j.bone.2010.03.021
    - TAVORMINA, P. L.; BELLUS, G. A.; WEBSTER, M. K.; BAMSHAD, M. J.; FRALEY, A. E.; MCINTOSH, I.; SZABO, J.; JIANG, W.; JABS, E. W.; W, "A Novel Skeletal Dysplasia with Developmental Delay and Acanthosis Nigricans Is Caused by a Lys650Met Mutation in the Fibroblast Growth Factor Receptor 3 Gene", Am. J. Hum. Genet., (19990000), vol. 64, pages 722 - 731
    - GUDERNOVA, I.; VESELA, I.; BALEK, L.; BUCHTOVA, M.; DOSEDELOVA, H.; KUNOVA, M.; PIVNICKA, J.; JELINKOVA, I.; ROUBALOVA, L.; KOZUBI, "Multikinase Activity of Fibroblast Growth Factor Receptor (FGFR) Inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 Compromises the Use of Small Chemicals Targeting FGFR Catalytic Activity for Therapy of Short-Stature Syndromes", Hum. Mol. Genet., (20160000), vol. 25, doi:doi:10.1093/hmg/ddv441, pages 9 - 23, XP055574853

DOI:   http://dx.doi.org/10.1093/hmg/ddv441
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.